secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001104659-25-050441
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm receives FDA clearance to initiate Phase 3b trial of NurOwn for ALS
------------------------------------------------------------------------------

- FDA cleared Phase 3b trial under Special Protocol Assessment (SPA); endpoints agreed for future BLA.
- Trial to enroll ~200 participants at academic centers; 24-week double-blind phase plus 24-week open-label extension.
- Primary endpoint: change from baseline to week 24 on ALS Functional Rating Scale-Revised (ALSFRS-R).
- Company plans to activate sites in phases and secure funding via non-dilutive grants.
- Investor call and webcast scheduled for May 19 at 8:30 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925050441/0001104659-25-050441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925050441/tm2515509d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-050441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer